6.22 USD
0 (0%)
We assign a fundamental rating of 2 out of 10 to LJPC. LJPC was compared to 530 industry peers in the Biotechnology industry. While LJPC seems to be doing ok healthwise, there are quite some concerns on its profitability. LJPC is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year LJPC has reported negative net income.
1.2 Ratios
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.99% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | -5.53% | ||
| PM (TTM) | 8.54% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
LJPC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, LJPC has less shares outstanding
LJPC has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -12.76, we must say that LJPC is in the distress zone and has some risk of bankruptcy.
LJPC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -12.76 |
ROIC/WACCN/A
WACC9.48%
2.3 Liquidity
A Current Ratio of 4.02 indicates that LJPC has no problem at all paying its short term obligations.
A Quick Ratio of 3.52 indicates that LJPC has no problem at all paying its short term obligations.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.02 | ||
| Quick Ratio | 3.52 |
3. Growth
3.1 Past
The earnings per share for LJPC have decreased by 0.00% in the last year.
LJPC shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -33.79%.
LJPC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 161.44% yearly.
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.27%
Revenue 1Y (TTM)-33.79%
Revenue growth 3Y95.98%
Revenue growth 5Y161.44%
Sales Q2Q%-34.35%
3.2 Future
LJPC is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 38.81% yearly.
LJPC is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.65% yearly.
EPS Next Y-92.84%
EPS Next 2Y-35.85%
EPS Next 3Y-5.61%
EPS Next 5Y38.81%
Revenue Next Year-31.93%
Revenue Next 2Y-9.19%
Revenue Next 3Y-0.71%
Revenue Next 5Y6.65%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for LJPC. In the last year negative earnings were reported.
LJPC is valuated quite expensively with a Price/Forward Earnings ratio of 26.51.
The average S&P500 Price/Forward Earnings ratio is at 23.88. LJPC is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 26.51 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | -120.41 |
4.3 Compensation for Growth
A cheap valuation may be justified as LJPC's earnings are expected to decrease with -5.61% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-35.85%
EPS Next 3Y-5.61%
5. Dividend
5.1 Amount
No dividends for LJPC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:LJPC (8/19/2022, 8:00:02 PM)
6.22
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners0%
Inst Owner Change0%
Ins Owners6.25%
Ins Owner Change0%
Market Cap158.96M
Revenue(TTM)46.49M
Net Income(TTM)3.97M
Analysts43.33
Price Target6.35 (2.09%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 26.51 | ||
| P/S | 3.42 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | -120.41 |
EPS(TTM)-0.03
EYN/A
EPS(NY)0.23
Fwd EY3.77%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS1.82
BVpS-2.72
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.99% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | -5.53% | ||
| PM (TTM) | 8.54% | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.47
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.02 | ||
| Quick Ratio | 3.52 | ||
| Altman-Z | -12.76 |
F-Score7
WACC9.48%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.27%
EPS Next Y-92.84%
EPS Next 2Y-35.85%
EPS Next 3Y-5.61%
EPS Next 5Y38.81%
Revenue 1Y (TTM)-33.79%
Revenue growth 3Y95.98%
Revenue growth 5Y161.44%
Sales Q2Q%-34.35%
Revenue Next Year-31.93%
Revenue Next 2Y-9.19%
Revenue Next 3Y-0.71%
Revenue Next 5Y6.65%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A
LA JOLLA PHARMACEUTICAL CO / LJPC FAQ
What is the ChartMill fundamental rating of LA JOLLA PHARMACEUTICAL CO (LJPC) stock?
ChartMill assigns a fundamental rating of 4 / 10 to LJPC.
Can you provide the valuation status for LA JOLLA PHARMACEUTICAL CO?
ChartMill assigns a valuation rating of 3 / 10 to LA JOLLA PHARMACEUTICAL CO (LJPC). This can be considered as Overvalued.
Can you provide the profitability details for LA JOLLA PHARMACEUTICAL CO?
LA JOLLA PHARMACEUTICAL CO (LJPC) has a profitability rating of 6 / 10.
How financially healthy is LA JOLLA PHARMACEUTICAL CO?
The financial health rating of LA JOLLA PHARMACEUTICAL CO (LJPC) is 3 / 10.
What is the earnings growth outlook for LA JOLLA PHARMACEUTICAL CO?
The Earnings per Share (EPS) of LA JOLLA PHARMACEUTICAL CO (LJPC) is expected to decline by -92.84% in the next year.